CTIS2022-501179-23-00招募中1 期
Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial - RC22_0378
Centre Hospitalier Universitaire De Nantes0 个研究点目标入组 256 人开始时间: 2022年11月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Age = 12 years, Moderate to severe AD treated with dupilumab every 2 weeks, Written informed consent (patient and/or person who has parental authority), Dupilumab treatment for at least one year, Controlled AD (ADCT<7 and IGA = 2) and assessed as controlled by the investigator since at least 6 months without tapering dosage of dupilumab, Amount of topical treatment (TCS or calcineurin inhibitor) stable for 6 months and less than 60 g/month
排除标准
- •Amount of topical treatment (TCS or calcineurin inhibitor) stable for 6 months and less than 60 mg/month, Non controlled AD: ADCT = 7 or IGA = 3, Female patient must not be pregnant, breastfeeding or considering becoming pregnant, Patient under judicial protection, Adults under guardianship or trusteeship
研究者
相似试验
进行中（未招募）
4 期
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic DermatitisAtopic DermatitisEczema, AtopicNCT05642208Nantes University Hospital256
进行中（未招募）
1 期
Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance or biochemical relapse is effective in preventive therapy.Multiple Myeloma and Minimal Residual DiseaseMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-003253-41-PLPolish Myeloma Consortium274
招募中
1 期
DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry.Atopic eczemaMedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785CTIS2023-504171-24-00Amsterdam UMC216
招募中
2 期
se of a new medicine Daratumumab to treat left-over cancer in a blood cancer called T-Acute Lymphoblastic LeukemiaCTRI/2023/07/054825ady Tata Memorial Trust
已完成
2 期
Dupilumab in CRSsNPChronic Rhinosinusitis Without Nasal PolypsChronic SinusitisSinus DisorderRespiratory DisorderSinusitisNCT04678856Sanofi71